Pfizer’s $99 Billion Bid for AstraZeneca Is a Tax Shelter

Pfizer’s $98.7 billion offer for AstraZeneca is hostile on multiple fronts: The London-based target has spurned the offer as too low, while the cost to the U.S. Treasury is potentially high.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.